Search

Wolfgang J Wrasidlo

from La Jolla, CA
Age ~86

Wolfgang Wrasidlo Phones & Addresses

  • 1849 Caminito Brisa, La Jolla, CA 92037 (858) 746-9422
  • 307 Prospect St, La Jolla, CA 92037 (858) 454-2796 (858) 456-9422
  • Apple Valley, CA
  • San Diego, CA
  • La Mesa, CA

Work

Company: University of california, san diego Position: Director med chem core at ucsd

Skills

Research • Molecular Biology • Biochemistry • Science • Cell Culture • Pcr • Clinical Research • Data Analysis • Lifesciences • Microscopy

Industries

Nanotechnology

Resumes

Resumes

Wolfgang Wrasidlo Photo 1

Director Med Chem Core At Ucsd

View page
Location:
402 Dickinson St, San Diego, CA 92103
Industry:
Nanotechnology
Work:
University of California, San Diego
Director Med Chem Core at Ucsd
Skills:
Research
Molecular Biology
Biochemistry
Science
Cell Culture
Pcr
Clinical Research
Data Analysis
Lifesciences
Microscopy

Publications

Us Patents

Vasculostatic Agents And Methods Of Use Thereof

View page
US Patent:
7208493, Apr 24, 2007
Filed:
Oct 2, 2003
Appl. No.:
10/679209
Inventors:
Wolfgang Wrasidlo - La Jolla CA, US
John Doukas - Encinitas CA, US
Ivor Royston - La Jolla CA, US
Glenn Noronha - Oceanside CA, US
John D. Hood - San Diego CA, US
Elena Dneprovskaia - San Diego CA, US
Xianchang Gong - San Diego CA, US
Ute Splittgerber - La Mesa CA, US
Ningning Zhao - San Diego CA, US
Assignee:
TargeGen, Inc. - San Diego CA
International Classification:
A61K 31/4985
C07D 471/02
US Classification:
514249, 544256
Abstract:
Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases , inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.

Benzotriazine Inhibitors Of Kinases

View page
US Patent:
7456176, Nov 25, 2008
Filed:
Apr 7, 2005
Appl. No.:
11/102405
Inventors:
Glenn Noronha - Oceanside CA, US
Kathy Barrett - La Jolla CA, US
Jianguo Cao - San Diego CA, US
Colleen Gritzen - Vista CA, US
Xianchang Gong - San Diego CA, US
John D. Hood - San Diego CA, US
Chi Ching Mak - San Diego CA, US
Andrew McPherson - San Diego CA, US
Ved Prakash Pathak - San Diego CA, US
Joel Renick - San Diego CA, US
Richard M. Soll - San Diego CA, US
Ute Splittgerber - La Mesa CA, US
Wolfgang Wrasidlo - La Jolla CA, US
Binqi Zeng - San Diego CA, US
Ningning Zhao - San Diego CA, US
Elena Dneprovskaia - San Diego CA, US
Assignee:
TargeGen, Inc. - San Diego CA
International Classification:
C07D 401/12
C07D 401/14
C07D 403/04
C07D 403/12
C07D 403/14
C07D 413/12
C07D 413/14
C07D 417/12
C07D 417/14
A61K 31/53
A61P 19/02
A61P 35/00
US Classification:
514243, 544183
Abstract:
The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases.

Heterocyclic Compounds And Methods Of Use

View page
US Patent:
7652051, Jan 26, 2010
Filed:
Aug 24, 2005
Appl. No.:
11/212064
Inventors:
Wolfgang Wrasidlo - La Jolla CA, US
Elena Dneprovskaia - San Diego CA, US
Assignee:
TargeGen, Inc. - San Diego CA
International Classification:
C07D 401/12
C07D 401/14
C07D 403/12
C07D 403/14
C07D 413/14
A61K 31/4192
A61P 19/02
A61P 35/00
US Classification:
514383, 514384, 514269, 514275, 5142315, 51425213, 51425214, 5482622, 544311, 544312, 544321, 544323, 544359, 544111, 544114, 546192, 546193, 5462681
Abstract:
Heterocyclic compounds derived from benzotriazine, triazines, triazoles and oxadiazoles are disclosed. The methods of synthesis and of use of such heterocyclic compounds are also provided.

Heterocyclic Compounds And Methods Of Use

View page
US Patent:
8084618, Dec 27, 2011
Filed:
Jan 8, 2010
Appl. No.:
12/684312
Inventors:
Wolfgang Wrasidlo - La Jolla CA, US
Elena Dneprovskaia - San Diego CA, US
Assignee:
TargeGen, Inc. - San Diego CA
International Classification:
C07D 401/12
C07D 401/14
C07D 403/12
C07D 403/14
C07D 413/14
A61K 31/4245
A61K 31/506
A61P 19/02
A61P 35/00
US Classification:
548131, 548132, 514364, 5142315, 514269, 51425213, 514340, 544111, 544298, 544359, 5462691
Abstract:
Heterocyclic compounds derived from benzotriazine, triazines, triazoles and oxadiazoles are disclosed. The methods of synthesis and of use of such heterocyclic compounds are also provided.

Wnt Signaling Inhibitors, And Methods For Making And Using Them

View page
US Patent:
8304408, Nov 6, 2012
Filed:
May 15, 2008
Appl. No.:
12/600996
Inventors:
Wolfgang Wrasidlo - La Jolla CA, US
Catriona H. Jamieson - La Jolla CA, US
Dennis Carson - La Jolla CA, US
Tadeusz F. Molinski - La Jolla CA, US
Desheng Lu - La Jolla CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 31/35
A61P 35/02
US Classification:
51421206, 51421207
Abstract:
The invention provides dBHD-based compositions and dBHD analog compositions, and pharmaceutical compositions comprising them, e. g. , in the form of liposomes and nanoparticles comprising them, and methods of making and using them. In one embodiment, these dBHD analogs are used to inhibit a dysfunctional stem cell and/or a cancer (tumor) stem cell.

Conjugates Of Synthetic Tlr Agonists And Uses Therefor

View page
US Patent:
8357374, Jan 22, 2013
Filed:
Feb 7, 2008
Appl. No.:
12/027960
Inventors:
Dennis A. Carson - La Jolla CA, US
Wolfgang Wrasidlo - La Jolla CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 39/385
A61K 45/00
A61K 47/00
A61K 9/127
A61K 31/522
A01N 43/90
C07D 473/00
US Classification:
4241941, 4242781, 4241841, 424450, 977917, 977915, 51426337, 544276
Abstract:
The invention provides TLR agonists and conjugates thereof useful in vaccines and to prevent, inhibit or treat a variety of disorders including pathogen infection and asthma.

Heterocyclic Compounds And Methods Of Use

View page
US Patent:
8372971, Feb 12, 2013
Filed:
Sep 23, 2011
Appl. No.:
13/243924
Inventors:
Wolfgang Wrasidlo - La Jolla CA, US
Elena Dneprovskaia - San Diego CA, US
Assignee:
TargeGen, Inc. - Bridgewater NJ
International Classification:
C07D 401/12
C07D 401/14
C07D 403/12
C07D 403/14
C07D 413/12
C07D 413/14
C07D 417/12
C07D 417/14
A61K 31/53
A61P 19/02
A61P 35/00
US Classification:
544183, 514243
Abstract:
Heterocyclic compounds derived from benzotriazine, triazines, triazoles and oxadiazoles are disclosed. The methods of synthesis and of use of such heterocyclic compounds are also provided.

Compounds For Inhibiting Protein Aggregation, And Methods For Making And Using Them

View page
US Patent:
8450481, May 28, 2013
Filed:
Jun 13, 2008
Appl. No.:
12/602689
Inventors:
Eliezer Masliah - San Diego CA, US
Igor Tsigelny - San Diego CA, US
Wolfgang Wrasidlo - La Jolla CA, US
Edward Rockenstein - Chula Vista CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C07D 417/04
A61K 9/127
A61K 31/4985
US Classification:
544279, 424450, 514249
Abstract:
The invention provides compositions comprising protein aggregation inhibitors, and pharmaceutical compositions comprising them, and methods for making and using them, including methods for preventing, reversing, slowing or inhibiting protein aggregation, e. g. , for treating diseases that are characterized by protein aggregation—including some degenerative neurological diseases such as Parkinson's disease. In one aspect, the compositions of the invention specifically target synuclein, beta-amyloid and/or tau protein aggregates, and the methods of the invention can be used to specifically prevent, reverse, slow or inhibit synuclein, beta-amyloid and/or tau protein aggregation. In alternative embodiments, the compositions and methods of the invention, are used to treat, prevent or ameliorate (including slowing the progression of) degenerative neurological diseases related to or caused by protein aggregation, e. g. , synuclein, beta-amyloid and/or tau protein aggregation. In one aspect, compositions and methods of this invention are used to treat, prevent or ameliorate (including slowing the progression of) Parkinson's disease, Alzheimer's Disease (AD), Lewy body disease (LBD) and Multiple system atrophy (MSA).
Wolfgang J Wrasidlo from La Jolla, CA, age ~86 Get Report